Protection after the second dose of Moderna’s coronavirus vaccine remains strong after six months, according to a statement in advance of the company’s earnings call.
The data came from a new analysis of Moderna’s clinical trial data that included 30,000 American volunteers. In November 2020, the company announced that the vaccine was 94.1% efficient, and the latest analysis shows that rate didn’t change much after six months. Both Pfizer and BioNTech said their vaccine efficacy declined to around 84% after six months.
The statement also says that Moderna anticipates boosters will be necessary this fall. The company announced that it has tested potential booster shots, which bring antibodies back to the protective levels triggered by full vaccination.
Moderna filed for final approval of its vaccine on June 1, 2021 and expects to complete its submission in August. The U.S. Food and Drug Administration (FDA) is expected to give full approval to the Pfizer-BioNTech vaccine next month.
References
- Moderna, Inc. Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates. (2021). Retrieved from: https://investors.modernatx.com/news-releases/news-release-details/moderna-reports-second-quarter-fiscal-year-2021-financial